Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
— Casimersen is designed for the treatment of exon 45 amenable patients, approximately eight percent of patients with Duchenne —— […]